During the 2023 Safety Pharmacology Society (SPS) Conference in Brussels, scientists from leading preclinical contract organizations (CROs) discussed how traditional IND-enabling studies involving primates and dogs can be complemented (and sometimes even replaced) by alternative models such as mice, rats, rabbits and pigs.
Dr. Donald Hodges (CBSET, MA, USA) discussed the history, regulatory framework and other factors influencing species selection in IND-enabling studies.
He outlined how proven translational characteristics and historical data are enabling the wider adoption of swine as an alternative to dogs and Non-Human Primates in the context of shortages and rising costs.
This article summarizes some of the key points that were presented during the event and includes the video recording of the talk.
